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The prevalence of obesity is a growing health problem. Obesity is strongly associated 
with several comorbidities, such as non-alcoholic fatty liver disease, certain cancers, 
insulin resistance, and type 2 diabetes, which all reduce life expectancy and life quality. 
Several drugs have been put forward in order to treat these diseases, but many of them 
have detrimental side effects. The unexpected role of the family of fibroblast growth fac-
tors in the regulation of energy metabolism provides new approaches to the treatment 
of metabolic diseases and offers a valuable tool to gain more insight into metabolic 
regulation. The known beneficial effects of FGF19 and FGF21 on metabolism, together 
with recently discovered similar effects of FGF1 suggest that FGFs and their derivatives 
carry great potential as novel therapeutics to treat metabolic conditions. To facilitate 
the development of new therapies with improved targeting and minimal side effects, a 
better understanding of the molecular mechanism of action of FGFs is needed. In this 
review, we will discuss what is currently known about the physiological roles of FGF 
signaling in tissues important for metabolic homeostasis. In addition, we will discuss 
current concepts regarding their pharmacological properties and effector tissues in 
the context of metabolic disease. Also, the recent progress in the development of FGF 
variants will be reviewed. Our goal is to provide a comprehensive overview of the current 
concepts and consensuses regarding FGF signaling in metabolic health and disease and 
to provide starting points for the development of FGF-based therapies against metabolic 
conditions.
Keywords: fibroblast growth factors, metabolic syndrome, FGF signaling, therapeutic potential, FGF1, FGF19, 
FGF21
iNTRODUCTiON
Fibroblast growth factors (FGFs) are secreted signaling proteins with wide ranging functions in 
cell proliferation, development, and wound healing (1, 2). FGFs act as autocrine, paracrine, and/
or endocrine hormones by binding to FGF receptors (FGFRs). FGFR dimerization induces the 
activation of downstream signaling cascades. Over the past two decades, several FGFs have been 
linked to metabolism by the discovery that they are transcriptionally regulated by members of the 
nuclear receptor (NR) superfamily of ligand-activated transcription factors (3–8). These FGFs have 
been demonstrated to mediate some of the effects of these NRs in the regulation of glucose and lipid 
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metabolism (3, 9, 10). Currently, three members have been linked 
to regulation of energy metabolism: FGF1, FGF15/19 (with FGF15 
being the mouse ortholog of human FGF19), and FGF21 (3–6). 
FGF1 is critical for adipose function and is regulated by the lipid 
sensor PPARγ, FGF15/19 modulates bile acid metabolism and is 
regulated by the bile acid sensor farnesoid X receptor (FXR), and 
FGF21 regulates the adaptive fasting response and is a target of 
the fatty acid sensor PPARα (3, 9, 10).
FGF15/19 is considered as a regulator of the feeding response. 
In response to food intake, a postprandial flux of bile acids is 
released into the small intestine followed by activation of FXR 
expressed in the terminal ileum, which results in increased 
transcription of FGF15/19 (9). FGF15/19 enters the circulation 
and binds to the FGFR4/β-klotho receptor complex on the cell 
membrane of hepatocytes, ultimately leading to repression 
of   gluconeogenesis and stimulation of glycogen and protein 
synthesis (11).
FGF21 is considered a typical fasting hormone and although 
seemingly paradoxical, circulating FGF21 levels are also elevated 
during obesity (12). The link between obesity and prolonged 
fasting is that they are both characterized by increased levels of 
circulating free fatty acids (FFAs), which can activate PPARα 
in the liver, leading to upregulation of FGF21 (13). In addition, 
FGF21 is secreted by the muscle during situations of metabolic 
stress [reviewed in Ref. (14)]. FGF21 acts on different tissues, 
including brain, adipose tissues, pancreas, and the liver [reviewed 
in Ref. (15)].
FGF1 is expressed in several tissues, including the liver, kid-
ney, and brain, but most notably it is highly upregulated in white 
adipose tissue (WAT) following a high fat diet (HFD) challenge. 
Experiments with FGF1 KO mice revealed that this growth factor 
is indispensable for WAT remodeling in response to feeding and 
fasting. Mice lacking FGF1 are unable to properly expand their 
WAT during increased nutrient load, and upon withdrawal of the 
HFD, also have problems in WAT reduction (3).
When overexpressed or pharmacologically administered to 
obese, diabetic animals, FGF1, FGF19, and FGF21 all greatly 
improve the metabolic profile (4, 16, 17). Acute effects include 
lowering of blood glucose and insulin levels (16, 18). Chronic 
administration of any one of these FGFs results in increased insu-
lin sensitivity, reduced hepatic steatosis (fatty liver), and improved 
serum lipid profiles. FGF15/19 and FGF21 also promote weight 
loss (18). FGF1, FGF19, and FGF21 regulate different metabolic 
processes through different cell types and tissues, of which the 
WAT, CNS, and the liver seem to be the main players (3, 4, 11, 14, 
16, 18, 19). In addition, brown adipose tissue (BAT), pancreas, 
and muscle are involved in FGF signaling by being a source of 
FGFs, a target, or both (20–25).
FGF1, FGF15/19, FGF21, and their targets provide interesting 
therapeutic possibilities for the treatment of metabolic diseases, 
such as obesity, non-alcoholic fatty liver disease, type 2 diabetes, 
and atherosclerosis (3, 4, 17). Despite their spectacular metabolic 
properties, the native FGFs do not have the optimal characteristics 
to be used as a drug in the clinic (26, 27). However, considerable 
progress has been made in the development of highly improved 
FGF mutants and variants, one of which has already entered a 
clinical trial (28).
With this review, we aim to provide a comprehensive overview 
of the current concepts regarding FGF signaling in metabolic 
health and disease, and to provide starting points for the develop-
ment of FGF-based therapies for metabolic diseases.
FGF SiGNALiNG MACHiNeRY
The FGF family consists of 18 members affecting a variety 
of processes through induction of intracellular signaling via 
their cognate receptors, the FGFRs (29). There are four FGFRs 
(FGFR1–4) with an intracellular tyrosine kinase domain, and one 
that lacks this domain (FGFRL1/FGFR5) (30). Depending on the 
tissue, alternative splicing of these genes gives rise to a total of 
seven different isoforms (FGFR1b, FGFR1c, FGFR2b, FGFR2c, 
FGFR3b, FGFR3c, and FGFR4) due to the alternative use of exon 
IIIb or IIIc (29).
FGF1 is often called the universal ligand as it can bind and 
activate all FGFRs (31). It does, however, require polysulfated 
polysaccharides such as heparan sulfate proteoglycans (HSPGs) 
or heparin on the cell membrane to form a stable signaling 
complex to induce efficient signaling (32). These polysaccharides 
are present on the cell membrane of almost all cell types. It is 
thought that the high affinity of FGF1 and other canonical FGFs 
for HSPGs restricts their activity to the vicinity of its secretory 
point, and that they therefore mainly act as autocrine or paracrine 
factors (33). The interaction of FGF1 with integrins, another type 
of cell surface receptor, also contributes to its activity (34, 35).
FGF15/19 and FGF21 have lower affinities for HSPGs and 
thus can circulate through the body. They rely on the membrane-
bound co-receptor β-klotho to establish FGFR activation (36, 37). 
Depending on the secreting tissue, FGF15/19 and FGF21 can act 
as endocrine and/or autocrine factors. FGF21 mainly binds to 
FGFR1, while FGF19 associates with both FGFR1 and FGFR4 
to a similar extent (38). The tissue-specific activity of an FGF is 
thus determined by its affinity for the different FGFRs together 
with its requirement for binding to polysulfated polysaccharides, 
β-klotho and integrins (39).
Binding of an FGF to its receptors and cofactors induces 
dimerization and subsequent phosphorylation of the receptor 
intracellular tyrosine kinase domains, which then function as 
docking sites for other signaling proteins (40). Two main signal-
ing proteins that associate with FGFRs upon receptor activation 
are phospholipase C (PLCγ) (41) and FGF receptor substrate 2 
(FRS2) (42). PLCγ links FGFR activation to downstream changes 
in diacylglycerol (DAG), inositol triphosphate (IP3), intracel-
lular Ca2+ levels, and activation of protein kinase Cs (PKCs). 
FRS2 facilitates the assembly of a scaffold complex [consisting 
of protein tyrosine phosphatase, non-receptor type 11 (Shp2), 
growth factor receptor-bound protein 2 (Grb2), and GRB2-
associated-binding protein 1 (GAB1)] that mediates Ras/MAPK/
ERK and PI3K–Akt signaling (31, 40, 43). Other studies showed 
that FGFRs can stimulate STAT3 activation (44). FGF-induced 
downstream signaling pathways and concomitant intracellular 
changes are tissue and cell type dependent.
The expression of β-klotho, FGFR1c, and FGFR2c is downreg-
ulated in WAT during obesity and inflammation (45). Pancreatic 
β-klotho is downregulated under hyperglycemic conditions (46). 
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This indicates that FGF signaling is not only regulated by the 
time- and tissue-dependent expression of the ligands but also by 
their signaling machinery, which can be affected by pathologi-
cal conditions. This further substantiates the intricate interplay 
between FGFs, receptors, and cofactors and their effect on 
metabolic homeostasis.
FGF SiGNALiNG iN wHiTe ADiPOSe 
TiSSUe
Adipocytes express both β-klotho and FGFRs (mainly FGFR1c 
and FGFR2c) and are therefore putative targets for FGFs, as 
illustrated in Figure  1 (47). WAT is also a source of FGFs, of 
which FGF1 and FGF21 are most relevant in the adult (3, 48). 
The adipose-tissue-specific FGFR1 KO mouse model has been 
particularly useful in unraveling the contribution of WAT to the 
beneficial effects of FGFs on metabolism. However, these mice 
were generated by Cre-recombinase-mediated deletion using 
the aP2 promoter, which is known for its ectopic expression in 
macrophages and neuronal cells (49). Several brain areas also 
express FGFR1 and have been shown to be involved in regulat-
ing responses to FGFs (50, 51). It is unknown whether there are 
neurons that co-express aP2 and FGFR1, which would result in 
excision of FGFR1, and defective FGFR1 signaling in the brain. 
Therefore, conclusions based on this model should be drawn with 
some caution.
FGF1
Compared to lean controls, obese patients display a higher 
subcutaneous WAT-specific secretion of FGF1, as determined 
by ex vivo secretion assays (52). Adipose-derived FGF1 does not 
enter the circulation, suggesting that it acts locally (52). In mice, 
HFD feeding induces PPARγ-regulated FGF1 expression in vis-
ceral WAT, where it regulates responses to nutrient fluctuations. 
Knockout of FGF1 results in a defective response to HFD feeding 
characterized by aberrant WAT expansion and impaired WAT 
vascularization, the rapid development of severe diabetes, and 
defective WAT reduction upon HFD withdrawal (3). In contrast, 
FGF1 KO mice maintained on a normal chow diet show no obvi-
ous phenotype and appear completely normal.
How FGF1 is involved in the expansion of adipose tissue dur-
ing HFD feeding is not completely understood. However, there 
is evidence that FGF1 promotes pre-adipocyte proliferation and 
differentiation, and that ERK1/2 signaling is central to these pro-
cesses (53, 54). In addition, since FGF1 promotes angiogenesis, it 
is likely that locally produced FGF1 contributes to the expansion 
of WAT by stimulating vascularization (55). This hypothesis 
is supported by the finding that FGF1 KO mice show reduced 
vascularization of WAT after HFD feeding compared to control 
animals (3).
FGF1 is downstream of PPARγ, a well-known target for the 
thiazolidinedione (TZD) class of anti-diabetic drugs, leading to 
the hypothesis that FGF1 mediates a subset of PPARγ-activated 
genes, and by doing so improves the metabolic profile. Indeed, 
it has been shown that pharmacological administration of FGF1 
normalized blood glucose levels within an hour in obese, diabetic 
rodents. Chronic administration resulted in normoglycemia, 
insulin sensitization, and reduced hepatosteatosis (fatty liver). 
The acute blood glucose lowering effect seems to be dependent 
on FGFR1 signaling in WAT, since WAT-specific deletion of this 
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factor abrogated FGF1-induced normoglycemia in obese, hyper-
glycemic mice. Whether the other metabolic improvements (i.e., 
reduction of hepatic steatosis) are dependent on WAT signaling 
is unknown.
FGF19
FGF19 has high affinity for both FGFR1 and FGFR4 (38). It 
needs β-klotho to induce signaling through FGFR1c, 2c, and 
3c but can signal through FGFR4 independent of β-klotho (56). 
WAT is a putative target for FGF19, although it is believed that 
under normal physiological conditions the effects of endogenous 
FGF15/FGF19 are mainly mediated by the liver (5, 11, 17, 18). 
Pharmacological administration of FGF19 to obese diabetic 
rodents elicits beneficial effects on the metabolism that are highly 
similar to FGF21 administration (57).
In WAT-specific FGFR1 KO mice, FGF19 treatment still 
induced signaling in adipose tissue, and the beneficial effects 
on blood glucose levels were preserved. This might be explained 
by the fact that FGFR4 was upregulated in these mice, which 
possibly compensated for the loss of FGFR1 in the WAT (18). 
Along the same line, it was shown in ob/ob mice that an FGF19 
variant (FGF19dCTD) that could not interact with FGFR1–3 
but retained the ability to bind and activate FGFR4 was able 
to induce signaling in the liver but not in WAT. This mutant 
repressed CYP7A1 in the liver (which is a hallmark effect of 
hepatic FGF19 signaling) but failed to improve blood glucose 
levels in ob/ob mice (56). In accordance, another FGF19 variant 
with reduced affinity for FGFR4 but not FGFR1c was able to 
maintain its anti-diabetic effects (58). Finally, deletion of FGFR4 
in mice impaired FGF19-mediated bile acid regulation but not 
its effects on improvement of glucose tolerance (58). Together, 
these data indicate that the pharmacological effects of FGF19 rely 
on WAT signaling (mainly through FGFR1/β-klotho) to improve 
blood glucose homeostasis. It is very likely that FGF19 induces 
the same intracellular signaling as FGF21. Indeed, it has been 
shown that injection of FGF19 induced similar patterns in gene 
expression as compared to FGF21 (58). It is less clear whether the 
other beneficial effects of FGF19 on the obese metabolic profile 
(i.e., increased energy expenditure and weight loss after chronic 
treatment, improved lipid profile) are also mediated via WAT, 
or whether this requires additional signaling in other metabolic 
tissues such as liver. However, because FGF19 stimulates prolif-
eration in the liver it fell out of fashion as a putative drug to treat 
metabolic diseases (26).
FGF21
In contrast to FGF1, which mainly acts at the site of its produc-
tion, FGF15/19 and FGF21 not only act locally but can also 
escape into the circulation. FGF21 is mainly produced by the liver 
during times of metabolic stress, such as prolonged fasting (14). 
It is thought that one of the main targets is WAT, where FGF21 
regulates aspects of the fasting response (10). Studies with WAT-
specific FGFR1 KO mice indicate that FGF21 signaling through 
FGFR1/β-klotho in WAT protects the liver against steatosis during 
prolonged fasting by curbing lipolysis in WAT (59). In contrast, 
similar experiments in FGF21-overexpressing mice showed that 
FGF21 induces lipolysis in the WAT (10). These differences might 
be explained by compensatory regulation in knockout and trans-
genic models, non-specific effects by supra-physiological FGF21 
levels or by other experimental differences. Therefore, the effects 
of FGF21 on lipid metabolism in WAT during prolonged fasting 
remain elusive. In addition, it was shown that, similar to FGF1, 
FGF21 expression was induced in the WAT upon feeding, where 
it stimulated PPARγ activity and locally aids in adipogenesis (48).
Most data on FGF21 signaling in WAT come from experi-
ments in which FGF21 is pharmacologically administered or 
overexpressed in obese rodents, revealing potent effects on the 
amelioration of the metabolic profile during obesity (4, 60). 
Beneficial effects include lowering of plasma glucose, insulin, FFA 
and triglycerides, weight loss, and increased energy expenditure 
(4, 18, 60). In addition, FGF21 induces secretion of adiponectin, 
which was shown to be responsible for many of the effects of 
FGF21 in obese rodents. Studies in adiponectin-deficient animals 
showed that in these mice the acute beneficial effects of FGF21 are 
severely blunted, as are many of the chronic effects. Interestingly, 
the decrease in fat mass and body weight upon FGF21 treatment 
was still present in adiponectin-KO mice (albeit less than in 
FGF21-treated obese WT mice), indicating that these effects are 
independent of adiponectin (61, 62).
Signaling through the FGFR1/β-klotho complex is essential 
for many of the metabolic improvements that are induced 
upon FGF21 injection or overexpression in obese animals. KO 
or knockdown of β-klotho results in the ablation of FGF21 
signaling in WAT, both in  vitro and in  vivo, and eliminates its 
beneficial effects in obese rodents (37, 47, 63, 64). WAT-specific 
FGFR1 KO results in similar ablation of FGF21 signaling. In 
these mice, FGF21 treatment failed to reduce plasma glucose, 
insulin, and triglycerides, and no longer stimulated the secretion 
of adiponectin (18). The beneficial effects of FGF21 on serum 
FFAs and the reduction in hepatic steatosis, however, were still 
present (18). Together, these findings indicate that the glycemic 
effects are mediated via FGFR1/β-klotho signaling in WAT, while 
the improvement in serum FFAs and hepatic steatosis is possibly 
regulated via direct FGF signaling in the liver and/or brain.
Experiments in liver-specific insulin-receptor knockout 
mice (LIRKO mice) showed that FGF21 improved whole body 
insulin sensitivity and reversed hyperglycemia independent 
of insulin sensitization in the liver. On the other hand, intact 
hepatic insulin signaling was required for the FGF21-mediated 
improvement of circulating cholesterol and the reduction of 
hepatic triglycerides (65).
The intracellular signaling pathways conveying the FGF21-
induced metabolic changes in WAT are not completely under-
stood. The phosphorylation of FRS2α upon FGF21 treatment has 
been well established, both in vitro and in vivo. Also, strong tran-
sient activation of ERK1/2 has been reported in several different 
studies (4, 37, 38, 57, 66). In 3T3-L1 adipocytes, FGF21 acutely 
stimulated transient phosphorylation of Akt, phosphorylation of 
GSK3, SHP-2, P70S6K, STAT3, Raf-1, and induced calcium fluxes 
(66). Other acute phosphorylation events were found in pathways 
involved in insulin receptor signaling and the Phospholipase C 
signaling pathway (67). It has been hypothesized that the rapid 
blood glucose lowering after FGF21 administration is regulated 
by an ERK-dependent, Elk-1- and SRF-mediated increase in 
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GLUT1 expression in WAT (4, 68). However, the lowering of 
blood glucose by FGF21 in vivo is already apparent after 15 min, 
which is too fast for a process under transcriptional control (18). 
This indicates that other more acute signaling processes must be 
involved.
With respect to gene expression, a single FGF21 injection 
induced many changes in WAT, including changes in genes 
involved in FGF signaling, Wnt/β-catenin signaling, glucose 
uptake, amino acid transport, fatty acid oxidation, and lipid 
metabolism (60, 67). One of the main effects of chronic FGF21 
treatment is increased energy expenditure (60). It has been 
proposed that in WAT, this process this is mediated by LKB1, a 
protein kinase upstream of the major metabolic regulator AMPK. 
FGF21 activates LKB1, which activates AMPK by phosphoryla-
tion of Thr172. This leads to activation of Sirtuin 1 (SIRT1), which 
in turn switches on several other metabolic pathways that lead to 
increased energy expenditure (69).
It remains difficult to differentiate the long-term effects and 
gene expression data from direct signaling events in the adipose 
tissue, and to differentiate between primary effects of FGF21 on 
WAT, and secondary effects mediated by downstream effectors 
(such as adiponectin), FGF signaling in other tissues, and by 
responses to shifts in whole body metabolism.
THe eFFeCTS OF FGFS ON BROwN 
ADiPOSe TiSSUe AND BROwNiNG OF 
wAT
The main function of white adipocytes is to store energy, and 
brown adipocytes primarily burn energy and produce heat as a 
net result. They do so by converting chemical energy into heat 
through expression of uncoupling protein 1 (UCP1) in the mito-
chondrial membrane to uncouple substrate oxidation from ATP 
synthesis, thereby generating heat. BAT has gained increased 
attention as a putative target for the treatment of obesity and T2D 
due to its “fat-burning” properties and the recent demonstration 
that it is present in adult humans (70).
Evidence is also accumulating that FGF signaling is involved 
in the regulation of BAT and browning of WAT. BAT expresses 
FGFR1 and β-klotho but is also a source of FGF21. Upon cold 
exposure or β-adrenergic stimulation (classical stimuli for BAT 
activation), the expression and secretion of FGF21 from BAT is 
induced (29, 71–73). Based on these findings, a regulatory mecha-
nism has been proposed in which norepinephrine, released from 
the sympathetic nervous system in response to cold, increases 
cAMP levels by acting on β-adrenergic receptors in BAT. cAMP 
in turn activates PKA and p38 MAPK, which increase binding 
of the transcription factor ATF2 to the FGF21 promoter, thereby 
induce FGF21 gene transcription (73). BAT-derived FGF21 can 
act locally, or escape into the circulation to act on other tissues, 
and thus functions as an autocrine and endocrine factor involved 
in thermogenesis and responses to cold exposure. This is further 
supported by the observation that FGF21 KO mice display an 
impaired response to cold exposure (72). Another observation 
that stresses the importance of FGF21 in thermogenesis is 
that hepatic activation of PPARα by fatty acids from milk and 
subsequent induction of FGF21 is crucial for adequate BAT 
activation and thermogenesis in newborn mice (74).
Pharmacological FGF21 treatment or overexpression leads to 
an increase in expression of several genes and processes involved 
in thermogenesis in BAT. These include upregulation of UCP1 
and Acetyl CoA Carboxylase 2 (ACC2), increased core body 
temperature, and increased glucose uptake into BAT (60, 65, 
72, 75). In addition, FGF21 has also been shown to stimulate 
the expression of thermogenic genes and BAT markers (such as 
CIDEA and Cox7A) in WAT. The so-called “browning” of WAT 
is characterized by the appearance of brown-like adipocytes in 
WAT, a process normally induced by cold or β-adrenergic stimu-
lation (67, 72, 76, 77). PGC-1α, which is an important regulator 
of mitochondrial function, oxidative metabolism and thermo-
genesis, is crucial in the thermogenic effects of FGF21 on WAT 
and BAT. Knockout of PGC-1α greatly impaired the expression 
of thermogenic genes in response to FGF21 (72). In vitro treat-
ment of isolated primary WAT and BAT adipocytes with FGF21 
induced thermogenic gene expression (e.g., UCP1, PGC1-α, and 
cytochrome c). Unlike many other FGF-mediated processes, the 
FGF21-induced thermogenic gene expression seems to be ERK 
independent, since it was not impaired by addition of an ERK 
inhibitor to BAT cell cultures (72).
FGF21 does not acutely stimulate glucose uptake into brown 
adipocytes in vitro but is able to augment insulin-stimulated glu-
cose uptake (78). Prolonged (24 h) treatment of cultured brown 
adipocytes with FGF21 increased total respiration, uncoupled 
respiration, and glucose consumption (73). This indicates that 
FGF21 can directly act on BAT and the browning of WAT, and 
suggests a positive feedback loop in  vivo, where cold exposure 
leads to increased FGF21 expression and secretion, mediating 
upregulation of the thermogenic program. However, the effects 
of FGF21 on thermogenesis by regulating the nervous system 
cannot be excluded, since it has been shown that FGF21 also 
affects energy homeostasis via the brain, which in turn regulates 
neuronal output to peripheral organs (50, 51, 72, 73).
The finding that FGF21 directly activates the thermogenic 
program in BAT and WAT, and increases energy consumption 
in  vitro, suggested that its beneficial pharmacological effects 
in obese rodents might be mediated by BAT. However, this 
hypothesis has been severely challenged. Two groups indepen-
dently showed that surgical removal of BAT does not impair the 
pharmacological actions of FGF21 in obese rodents (79, 80). In 
addition, Véniant and colleagues showed that FGF21 retained 
most of its beneficial effects in UCP1 KO mice, indicating that 
BAT activation and WAT browning alone cannot account for 
the improved metabolic parameters upon FGF21 treatment (81). 
Similar observations were done by Samms et al. (82), who showed 
that UCP1 KO mice still displayed improved glycemic control 
and improved lipid profiles, and showed weight loss mainly due 
to decreased food intake. A recent study by Kwon and colleagues 
suggested that reductions in body weight upon FGF21 treatment 
is independent of UCP1, agreeing with the previous studies. 
However, their data suggest that FGF21-dependent glucose clear-
ance requires UCP1 protein (83).
In summary, several lines of evidence indicate that FGF21 plays 
an important role in the physiological response to cold exposure 
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by acting on the BAT. The notion that BAT increases FGF21 
expression upon cold exposure implies that there is a local feed-
back loop. In addition, since FGF21 also has endocrine effects, it 
cannot be excluded that BAT-derived FGF21 acts on other organs 
(i.e., brain and WAT) contributing to the cold response. However, 
there is substantial evidence that the pharmacological effects of 
FGF21 are not dependent on BAT but instead rely on other tissues 
such as the brain and WAT.
HePATiC FGF SiGNALiNG
Abundant expression of FGFR4 and β-klotho makes the liver an 
important target for FGFs in both mice and humans, as illustrated 
in Figure 1 (38, 84, 85). Next to WAT, the liver is the most inves-
tigated target and source of FGFs in the context of FGF signaling 
in metabolic homeostasis.
FGF19
The first indication that FGFs play a role in hepatic energy 
metabolism came from FGFR4 knockout mice which displayed 
increased bile acid production (86). Bile acids play an important 
role in nutrient absorption but can also function as signaling mol-
ecules through activation of bile acid receptors FXR and TGR5 
(87). The discovery that postprandial production of FGF15/19 
in the ileum is transcriptionally controlled by FXR provided an 
essential lead toward elucidating the regulatory mechanism of 
bile acid homeostasis (88). FGF15/19 was shown to negatively 
regulate bile acid production by activation of FGFR4/β-klotho 
on hepatocytes and subsequent suppression of CYP7A1 and 
CYP8B1, genes that encode the rate-limiting enzymes in bile acid 
synthesis (88). This FGF19-induced repression required both the 
activation of the c-Jun N-terminal kinase (JNK) and the ERK 
signaling pathway (89).
Injection or overexpression of FGF19 lowered blood glucose 
levels and triglycerides in diabetic mice, and protected against 
diet-induced obesity (5, 17). Conversely, KO of FGFR4, the pref-
erential receptor for FGF15/19, caused hyperlipidemia, glucose 
intolerance, and insulin resistance. Surprisingly, however, FGFR4 
KO mice were protected against HFD-induced hepatic steatosis. 
The same study showed by re-expressing hepatic FGFR4 in 
FGFR4 KO mice that FGFR4 in the liver was indispensable for 
whole body lipid metabolism but not required for whole body 
glucose metabolism (90).
Kir and colleagues showed that FGF15/19 does affect hepatic 
glucose metabolism by acting as an insulin-independent stimula-
tor for protein and glycogen synthesis (11). Unlike insulin, which 
predominantly relies on the Akt–mTOR axis to influence these 
processes, i.v. injection of FGF19-stimulated protein and glycogen 
synthesis via FGFR4–ERK–RSK signaling. This in turn resulted 
in repression of the α- and β-isoforms of GSK3, de-repression 
of glycogen synthase, and enhanced glycogen storage. The same 
pathway also resulted in activation of eukaryotic initiation factors 
eIF4B and ribosomal protein S6 by RSK, leading to stimulation of 
protein synthesis in HepG2 cells as well as in mice (11).
Inhibition of the insulin-induced signaling cascade during 
insulin resistance occurs to a large extent upstream of Akt. FGF 
signaling therefore bypasses this upstream inhibition, while 
downstream processes such as glycogen and protein synthesis 
are activated, thereby mimicking insulin action. Insulin does 
not only stimulate glycogenesis but also promote lipogenesis 
through activation of sterol regulatory element-binding protein 
1c (SREBP-1c), and repression of lipolysis and mitochondrial 
function through inhibition of the transcription factor fork-
head box O1 (FOXO1), which causes hepatic triglyceride (TG) 
accumulation (91, 92). This steatotic effect was not observed in 
FGF19-treated mice. Finally, FGF19-induced ERK signaling was 
linked to repression of apolipoprotein A (APOA) in the liver, 
which is associated with athero-thrombotic disease (93).
A major finding regarding FGF signaling in the liver is that 
FGFR4 is responsible for FGF19-induced proliferation of hepato-
cytes and the induction of hepatocarcinomas (94). The observa-
tion that FGFR4 is involved in the regulation of proliferation 
led to the development of FGF variants that do not activate this 
receptor, so as to avoid mitogenesis (16, 26). This will be further 
discussed in the section about FGF mutants.
The upregulation of endogenously produced FGF15/19 may 
offer an alternative route to improve metabolism. It has been 
shown that gut-specific activation of FXR leads to increased 
FGF15 levels in mice and alterations in the bile acid plasma pool. 
Intestinal FXR activation did not lead to weight loss in obese mice 
but did improve several metabolic parameters. It is, however, 
unclear which of these effects are attributable to FGF15, and 
which ones to the changes in bile acid composition. In addition, it 
is unclear whether systemic upregulation of FGF15 in this model 
leads to increased hepatocarcinomas (95).
Together, these findings indicate that hepatic FGF19 signaling 
not only affects bile acid synthesis but also influences many other 
aspects of energy metabolism. Which receptors mediate these 
different responses is still unclear and is probably determined by 
the physiological state of the animal (i.e., normal body weight 
or obese, fed or fasted) and by the route of administration (i.e., 
overexpression, injection).
FGF21
The liver is an important source of FGF21. Experiments in mice 
with hepatic FGF21 overexpression suggested that FGF21 induces 
lipolysis in WAT, ketogenesis in the liver, reduction of physical 
activity, and induction of torpor (10). These are all aspects of a 
starvation response, in which the organism shifts from carbohy-
drates as an energy source to utilization of fatty acids released 
from the WAT, and in which ketone bodies are produced that 
supply the brain with energy. Based on the finding that mice with 
a liver-specific deletion of FGF21 displayed reduced peripheral 
insulin sensitivity, it has been hypothesized that upon refeeding 
after prolonged fasting, hepatic FGF21 communicates with other 
tissues to induce adequate refeeding responses, thereby helps in 
overcoming fasting-associated peripheral insulin-resistance (78).
Acute treatment of wild-type C57Bl/6 mice with FGF21-
induced hepatic FGF signaling, marked by FRS2α and ERK 
phosphorylation, and the induction of genes involved in hepatic 
gluconeogenesis, lipid metabolism, and ketogenesis (96). Chronic 
treatment of obese rodents with FGF21 reduced hepatic steatosis 
and improved insulin sensitivity, indicating that FGF21 treatment 
also improves liver function (75). These changes were associated 
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with reductions of SREBP-1 in the nucleus, and concomitant 
downregulation of several of its target genes, including genes 
involved in hepatic glycolysis, de novo fatty acid synthesis, and 
triglyceride synthesis. Repression of glucose-6-phosphatase was 
also found, suggesting repression of glycogenolysis (75).
It remains elusive how FGF21 mediates changes in the liver, 
and whether its effects are direct or indirect. The liver mainly 
expresses FGFR4, and only low levels of FGFR1, the preferential 
receptor for FGF21 (29, 38). FGF21 is unable to establish signaling 
through the FGFR4-β-klotho complex (38). Therefore, it remains 
to be determined whether the low levels of FGFR1 are sufficient 
to induce FGF21 signaling, or whether, for example, FGFR2 
and FGFR3, which are expressed at low levels in the liver, under 
certain circumstances might also contribute to hepatic FGF21 
signaling (29, 38). In addition, it is possible that the changes in 
hepatic metabolism in response to chronic FGF21 treatment are 
a consequence of a generally improved whole body metabolism, 
rather than a direct action of FGF21 on the liver.
FiBROBLAST GROwTH FACTORS AND 
MeTABOLiC ReGULATiON viA THe 
CeNTRAL NeRvOUS SYSTeM
It is well-established that peripheral signals such as adipokines 
and gastro-intestinal hormones (e.g., leptin and cholecystokinin) 
convey metabolic information to the brain and dynamically 
modulate the neuronal regulation of energy intake and glucose 
homeostasis (97). Disturbances or defects in this neuronal regu-
latory system of energy metabolism therefore often contribute 
to the development of obesity, metabolic syndrome, and type 2 
diabetes (98).
FGF1, β-klotho, and FGFRs are differentially expressed in 
several parts of the central nervous system (29, 99, 100). So far, no 
expression of FGF19 or FGF21 has been found in the brain (50), 
but it has been shown that FGF21 can easily enter the brain by 
diffusion, while FGF15/19 seems to lack this property and mainly 
stays in the peripheral circulation (101, 102).
Several lines of evidence now support a neuro-modulatory 
role for FGFs and their receptors in the central regulation of 
food intake, glucose homeostasis, and circadian behavior, and in 
mediating at least some of the pharmacological effects of FGFs 
(Figure 1). The recent finding that FGFR1 and FGFR4 expression 
in the rat hypothalamus are dramatically reduced in response to 
HFD further underlines the involvement of the FGF–FGFR axis 
in the central regulation of metabolism (100).
FGF1
FGF1 was the first member of the FGF family demonstrated 
to play a role in the neuronal regulation of food intake. Early 
studies in rats showed that feeding or intraperitoneal glucose 
injections increased FGF1 concentration in the cerebrospinal 
fluid. Ependymal cells lining the third cerebral ventricular wall 
are considered to be the primary source of this FGF1 (99). 
Subsequently, it was demonstrated that intra-cerebro-ventricular 
(i.c.v.) infusions of FGF1 suppressed food intake and inhibited 
the activity of FGFR1-containing glucose-sensitive neurons in 
the lateral hypothalamus (LHA), probably by activating PKC (25, 
99, 103). Conversely, neutralization of the biological activity of 
FGF1 by infusion of anti-FGF1 and/or FGFR1 antibodies into the 
LHA increased food intake (104, 105).
The generation of different FGF1 peptide fragments showed 
that the amino-terminal (1–15) of the molecule, but not the 
carboxyl-terminal, is responsible for the anorexic effect of FGF1 
(106). FGF1-induced feeding suppression is also strongly associ-
ated with the selective induction of heat shock protein 27 (HSP27) 
in hypothalamic astrocytes surrounding the third ventricle 
(107). However, the physiological relevance of increased HSP27 
expression and the role in FGF1-induced suppression of feeding 
behavior remains unclear. In addition to its effects on feeding, it 
has also been shown that i.c.v. infusion of FGF1 in rats resulted 
in a dramatic increase in slow wave sleep (i.e., deep sleep), which 
is considered a behavioral display of satiety that follows feeding 
(108). Although the effects of centrally administered FGF1 on 
food intake are quite clear, its effect on body composition and 
energy expenditure remain to be investigated. In addition, it is 
unknown whether peripherally administered FGF1 can cross the 
blood–brain barrier, and therefore whether the pharmacological 
effects of FGF1 are partly attributable to signaling in the brain.
FGF19
The presence of FGFR4 and β-klotho in the hypothalamus 
suggested that part of the metabolic actions of FGF19 could be 
mediated via the brain (100). Indeed, delivery of small doses of 
FGF19 directly into the brain has been shown to increase energy 
expenditure in mice (17). Moreover, i.c.v. infusion of FGF19 
reduced food intake and acutely improved glucose tolerance in 
both lean and diet-induced obese rats. Opposite effects on food 
intake and glucose tolerance were found when FGF signaling 
was blocked by central delivery of the FGFR inhibitor PD173074 
(100). Another study using ob/ob mice as a model supported 
these findings and suggested that a single i.c.v. infusion of FGF19 
improved glucose intolerance by increasing glucose disposal rate 
(24). In a rat model of type 1 diabetes, it was further shown that 
i.c.v. infusion of both FGF1 and FGF19 suppressed the hypo-
thalamic–pituitary–adrenal (HPA) axis, resulting in a decrease 
in hepatic glucose production, hepatic acetyl CoA content and 
whole-body lipolysis (109). However, a study on FGF19 kinetics 
showed that FGF19 enters the brain with low efficiency, and that 
after peripheral administration of supra-physiological doses only 
a small fraction enters the brain (102). It is therefore believed that 
both endogenously produced FGF15/19 and pharmacologically 
administered FGF19 mainly function via the peripheral tissues 
and not via the CNS.
FGF21
FGF21 is not expressed within the CNS but can enter the brain 
relatively easily, which allows for communication between 
peripheral tissues and the CNS (23).
The β-klothoCamk2a mouse, which lacks β-klotho expression 
in the hypothalamus and the hindbrain, has been instrumental 
in teasing out the central effects of FGF21 as opposed to its 
peripheral effects. Using this model, it was shown that, during 
normal physiology, central FGF21 signaling is required for the 
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regulation of circadian rhythms and the adaptive starvation 
response, which includes suppression of female reproduction 
and physical activity and the systemic increase of glucocorticoids 
(50). The central player in these processes is the hypothalamus, 
where FGF21 signaling suppressed arginine vasopressin (AVP), 
and stimulates corticotropin-releasing factor (CRF). Activation 
of the CRF–ACTH axis ultimately leads to adrenal glucocorticoid 
secretion, which in turn stimulates hepatic gluconeogenesis, thus 
providing an FGF21-mediated communication loop between 
the liver and the brain (50, 110). CRF can also activate BAT via 
sympathetic nervous output (111).
FGF21 signaling in the central nervous system has also been 
shown to be important for the beneficial effects of FGF21 in obese 
rodents. The first evidence came from experiments in which 
FGF21 was centrally infused into obese rats. This resulted in 
increased food intake, energy expenditure, and insulin sensitivity 
due to increased insulin-induced suppression of both hepatic glu-
cose production and gluconeogenic gene expression, but without 
changes in glucose utilization (51). Experiments with HFD-fed 
β-klothoCamk2a mice showed that β-klotho in the hypothalamus 
is needed to recapitulate the majority of the beneficial effects of 
FGF21 treatment during obesity. In obese, hypothalamic-defi-
cient β-klotho mice, the increase in energy expenditure, decrease 
in body weight, and subsequent improved changes in metabolic 
parameters, which normally occur upon chronic FGF21 admin-
istration, were all abrogated (19). This pointed toward the CNS 
as an important target for FGF21, both during normal physiology 
and during pharmacological treatment.
In conclusion, FGFs are able to affect the brain and modulate 
food intake and energy expenditure both during normal physiol-
ogy and in animal models of obesity. The brain should therefore 
be considered as a potential target of these growth factors in the 
treatment of metabolic diseases.
FGF SiGNALiNG iN THe ADULT 
PANCReAS
Although FGFs and FGFRs have long been known to play an 
important role in the embryonic development of the pancreas; 
more recently, it has been demonstrated that they also have a 
function in the adult pancreas (21, 112–114). In mice, the adult 
pancreas expresses β-klotho, moderate levels of FGFR1, but vir-
tually undetectable levels of the other three conventional FGFRs 
(29). The expression of FGF21 in pancreatic islets and isolated 
rat β-cells is well established (21, 29). The expression of other 
FGFs, however, is controversial. Some studies report the pres-
ence of FGF1, FGF2, FGF4, FGF5, FGF7, and FGF10 in β-cells 
(113), whereas others did not observe the expression of these 
factors (29).
Pancreatic FGF signaling has been linked to β-cell function 
by the discovery that disruption of FGFR1c-induced signaling 
in the pancreas accelerates the development of diabetes (113). 
Overexpression of a dominant-negative FGFR1c receptor in the 
pancreas caused β-cell dysfunction, decreased β-cell population, 
impaired expression of glucose transporter 2 (GLUT2), and aber-
rant insulin processing.
So far, the effects of FGF21–FGFR1 in β-cells and its effects 
on insulin secretion received the most attention because of its 
possible relevance to diabetes. Less well-studied is how FGF21 
injection or FGF21 incubation of islets works on α-cells and 
leads to the reported lowering in glucagon levels and glucagon 
secretion (4). In islets from non-obese, non-hyperglycemic 
rats, FGF21 has been shown to inhibit glucagon secretion but 
not insulin secretion (4). In another study, it was found that in 
islets from diabetic rodents FGF21 increased insulin content and 
secretion, and that FGF21 partially protected the islets from glu-
colipotoxicity and cytokine-induced apoptosis through ERK1/2- 
and Akt-dependent signaling mechanisms (21). In contrast, in 
islets isolated from healthy rats, FGF21 only increased insulin 
mRNA and protein levels but did not potentiate glucose-induced 
insulin secretion (21). Both in Ins-1E cells and in isolated rat 
islets, FGF21 treatment resulted in phosphorylation of FRS2α, 
Akt, and ERK1/2. The increase in insulin content upon FGF21 
treatment was ERK1/2 dependent, while the increased survival 
was suggested to be mediated via Akt and activation of BAD (21).
Another mechanism by which FGF21 could protect against 
HFD-induced metabolic stress in β-cells is via the repression of 
Acetyl-CoA carboxylase (ACC). ACC is the rate limiting enzyme 
for the conversion of citrate into malonyl-CoA, a substrate for 
long-chain fatty acid synthesis and potent inhibitor of mito-
chondrial transport and oxidation of fatty acids, two processes 
that contribute to β-cell malfunction (115). FGF21-treated islets 
showed decreased ACC expression and were protected against 
palmitate-induced toxicity (116).
A non-canonical FGF receptor, designated FGF receptor 5 
or FGF receptor-like 1 (FGFR5, FGFRL1) was also found to be 
expressed in the adult pancreas (117). FGFR5 localizes to the 
plasma membrane and to the insulin secretory granules (118). 
Unlike the canonical FGFRs, FGFR5 lacks an intracellular kinase 
domain and has therefore been postulated to function as a decoy 
receptor. Despite this, FGFR5 overexpression resulted in a ligand-
independent phosphorylation of ERK1/2, which was found to be 
dependent on the presence of the Src homology domain-2 (SH2)-
binding motif and the histidine-rich region in the C-terminal part 
of the receptor. Based on these findings, it has been proposed that 
binding of SHP-1 phosphatase to the SH2 domain leads to the 
ligand-independent activation of ERK1/2. FGFR5 overexpression 
in β-cells resulted in increased insulin content and secretion, and 
increased extracellular matrix adhesion. No effect, however, was 
observed on proliferation (118).
FGF SiGNALiNG iN MUSCLe
A role for FGFs in skeletal muscle regeneration was first described 
for FGF6, which is restricted to the myogenic lineage (119). 
FGF6-deficient mice show severe skeletal muscle regeneration 
defects characterized by fibrosis and myotube degeneration. It is 
believed that FGF6 primarily signals through FGFR4, since this 
receptor is highly expressed during myoblast differentiation and 
in recently formed myotubes (119, 120). Adult skeletal muscle tis-
sue, on the other hand, only expresses moderate levels of FGFR1, 
low levels of β-klotho, and very low to undetectable levels of the 
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other FGFRs (29, 85). The heart also expresses FGFR1 and low 
levels of β-klotho. Therefore, the skeletal muscle and heart are 
putative targets for FGFs in the adult.
It is unclear whether FGFs can influence energy homeostasis 
by directly acting on skeletal muscle tissue. Some studies report 
an improvement of glucose uptake into the muscle after FGF21 
injection in obese mice (which could be a direct or an indirect 
effect), while others did not find this (75, 121). In human cul-
tured myotubes, it has been found that FGF21 protected against 
palmitate-induced insulin resistance by affecting NF-κB signaling 
(122). In addition, FGF21 has been reported to stimulate glucose 
uptake in human cultured myotubes and mouse EDL muscle, but 
the signaling events involved in this process are unknown (22).
Although it remains unclear whether adult skeletal muscle is a 
direct target for FGFs in the context of metabolism, it is clear that 
it can be a source of FGF21. FGF21 protein was detected in mus-
cle of fasted mice and was upregulated in gastrocnemius muscle 
of skeletal muscle-specific Akt1-transgenic mice (123). Increased 
expression of FGF21 in skeletal muscle has also been described 
after exercise and in various pathological conditions, such as 
hyperinsulinema, mitochondrial myopathy, and lipodystrophy 
(124–128). In addition, increased skeletal muscle expression and 
circulating levels of FGF21 were found in patients with iron–sul-
fur cluster deficiency (129). It has been hypothesized that muscle 
derived FGF21 acts as a stress signal on adipocytes to maintain 
metabolic homeostasis (14). Whether the muscle is involved in 
mediating the pharmacological effects of FGF21, FGF19, or FGF1 
is unclear.
Similar to the skeletal muscle, the heart mainly expresses 
FGFR1 and low levels of β-klotho. Therapeutical treatment with 
either FGF1, FGF15/19, or FGF21 will therefore most likely also 
induce signaling in the heart. FGF2, which is very similar to FGF1, 
has been shown to affect cardiac remodeling through activation 
of MAPK [reviewed in Ref. (130)]. In addition, it has been shown 
that FGF21 KO mice are more susceptible to the development of 
cardiac hypertrophy also via activation of the MAPK signaling 
pathway (131). It is also possible that FGF21 signaling in the brain 
affects the sympathetic outflow to the heart, similar to BAT (19).
In conclusion, although the skeletal muscle and the heart can 
be targets for FGFs and are important for metabolic homeostasis, 
the effect of FGFs on these targets are largely unclear and poorly 
studied. However, proper assessment of the effects of FGF signal-
ing on these targets (especially on the heart) is needed for the 
development of safe FGF-based drugs.
FGF MUTANTS AND FGFR ANTiBODieS: 
PROMiSiNG PeRSPeCTiveS FOR  
FGF-BASeD PHARMACOLOGiCAL 
TReATMeNTS
The finding that FGFs play important roles in metabolic regula-
tion offers new therapeutic options for the treatment of metabolic 
disorders. However, despite their spectacular effects in rodents, 
wild-type FGFs have several drawbacks for use in patients. They 
have various adverse effects, are expensive and labor-intensive 
to produce, not suitable for large-scale production, and/or have 
poor stability and short half-life, which currently holds back their 
application (16, 26, 27, 132, 133). To circumvent this, several 
attempts have been made to improve the FGFs, so that they are 
more stable, retain, or improve their beneficial effects on metabo-
lism, and lose their side-effects.
The main concern that limits the application of FGF1 and 
FGF19 is that they have been linked to in vitro cellular prolifera-
tion and tumor formation, respectively (94, 134, 135). Although 
there are no indications that FGF21 is mitogenic, its chronic 
administration has been associated with bone loss (132). In addi-
tion, FGF1 and FGF21 have low in vivo stability, which would 
make treatment expensive and require multiple injections per 
week (27, 133). With regard to FGF1 and FGF19, attempts have 
been made to identify sequences within the peptide responsible 
for mediating the proliferative responses, and whether they can 
be deleted while retaining the metabolic properties. From stud-
ies with FGFR1 and FGFR4 KO mice and studies with FGF19 
mutants that show differential binding preference toward FGFR1 
and FGFR4 the concept arose that FGFR1 is the “metabolic” 
FGFR, while FGFR4 is the “proliferative” FGFR (18, 56, 58). 
This concept seems to be valid in many cases and has proved to 
be useful in the design of FGF variants with reduced mitogenic 
properties.
FGF1 Mutants
Already in the 90s, it has been shown that the N-terminus of 
FGF1 is involved in the proliferative properties of FGF1 [illus-
trated in Figure 2, Ref. (136)]. In addition, it has been shown that 
the N-terminus (amino acids 1–15) is important for the anorexic 
effects of FGF1 in the brain (106). More recently, the FGF1 variant 
FGF1dNT was described. This mutant lacks the first 24 amino 
acids from the N-terminus and shows reduced binding affinity 
for FGFR1 and 2, and virtually no affinity for FGFR3 and FGFR4. 
With the deletion of the N-terminus also the proliferative proper-
ties of FGF1dNT on the NIH 3T3 fibroblast cell line disappeared, 
while the in vivo insulin-sensitizing effects were conserved (16). 
Another FGF1 mutant, R50E no longer binds to integrin αvβ3 
but can still bind to FGFR1 and heparin (34). Although it can still 
stimulate transient ERK phosphorylation, this activation cannot 
be sustained and consequently shows reduced effects on cell 
proliferation and cell migration (137). Moreover, this mutant was 
able to suppress the angiogenic and tumorigenic effects of FGF1 
and FGF2 in several different in vivo and in vitro models (138).
As FGF1 can stimulate angiogenesis, it is currently under 
investigation for the treatment of ischemia and wound healing. 
However, its poor bio-stability currently limits its application. 
Attempts to improve the stability of the protein showed that 
changing a few amino acids within the protein (Lys12 → Val and 
Pro134 → Val) significantly improved the half-life and stability 
of FGF1 (133). Whether the FGF1 R50E mutant and the ther-
mostabilized mutant hold promise for FGF1-based treatment of 
metabolic disease remains to be determined.
FGF19 Mutants
FGF19 and FGF21 are structurally highly related, but FGF19 
has proliferative effects and stimulates tumorigenesis in the 
liver, whereas FGF21 does not have these properties (94). Using 
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FGF19/21 chimeric proteins, it has been shown that amino acid 
residues 38–42 of FGF19 are responsible for the activation of 
FGFR4 and proliferative effects on hepatocytes, a property that 
could be transferred to FGF21 (Figure 2). In addition, the β1–β2 
loop and the β10–β12 loop are required for heparin induced 
FGF19–FGFR4 signaling, and also contribute to the mitogenic 
properties of FGF19 (139). Deletion of the C-terminus abolished 
β-klotho interaction, thereby FGF19-induced signaling through 
FGFR1c, 2c, and 3c but retained FGFR4 activation through 
heparin-mediated stabilization of the signaling complex. This 
FGF19 mutant could still suppress bile acid synthesis, whereas 
beneficial effects on glucose metabolism and insulin sensitivity 
were abrogated (139). In contrast, an FGF19 variant with a modi-
fied N-terminus was no longer able to affect bile acid metabolism, 
whereas glucose levels and insulin sensitivity could still be 
beneficially influenced. Interestingly, this variant also lost its pro-
liferative properties, supporting the hypothesis that hepatocyte 
proliferation is dependent on activation of FGFR4 (26, 139).
FGF21 Mutants
Of all the metabolic FGFs, FGF21 received the most attention 
because of its beneficial effects on metabolism, while at the same 
time lacking proliferative properties. Using C-terminal and 
N-terminal deletion mutants, it has been shown that, similar to 
FGF19, the C-terminus of FGF21 is required for β-klotho interac-
tion, whereas the N-terminus drives efficient FGFR activation 
(Figure 2) (140, 142). Due to its poor stability and high production 
costs, most bioengineering research on FGF21 has been aimed at 
improving the stability and potency of the protein and bringing 
down the production costs. The results of this research have been 
recently extensively described (143, 144). In short, approaches to 
improve FGF21 bio-stability include the addition of an Fc frag-
ment to the N-terminus, the introduction of non-native disulfide 
bonds and subsequent PEG-ylation, and conjugation of FGF21 to a 
scaffold antibody (141, 145, 146). The most successful FGF21 vari-
ant is LY2405319, which entered clinical trials (28). This FGF21 
variant lacks the first four amino acids of the secretion signal, 
which reduces proteolysis at the N-terminus when the protein is 
expressed in yeast. The introduction of a non-native disulfide bond 
between Leu118 and Ala134 improved the stability of the peptide 
while substitution of Ser167 with an alanine reduced glycosylation 
and breakdown. Together, these modifications resulted in a protein 
that could be produced in yeast and is therefore suitable for large-
scale production, is more stable, but retained the metabolic effects 
of native FGF21 with similar potency (27). This mutant successfully 
lowered body weight, improved blood lipid profiles and increased 
insulin sensitivity in obese human subjects with type 2 diabetes. 
Blood glucose levels on the other hand were not significantly 
lowered, although a trend was apparent (28). Some side-effects 
were reported, such as hypersensitivity, elevated liver enzymes, 
injection site reactions, and headache, but the vast majority of the 
test subject tolerated the treatment considerably well.
The aforementioned examples of the different FGF variants 
indicate that the proliferative and metabolic properties of these 
peptide hormones are located at different sites within the mol-
ecule and are also transduced by different receptors and cofactors. 
In addition, small modifications of the peptide can influence 
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stability, purification, half-life, and production costs. Together, 
these options provide a window to tailor FGFs for specific phar-
macological needs.
MODULATiON OF MeTABOLiSM USiNG 
FGFR ANTiBODieS
In addition to modulation of FGFR signaling by modifying 
the ligands, it is also possible to target the FGFRs using specific 
activating or inhibiting antibodies. Antibodies that inhibit the 
proliferative FGFR-mediated signals have been extensively inves-
tigated for the development of anti-cancer drugs [reviewed in Ref. 
(147)]. More recently this approach has also been explored in the 
treatment of metabolic disease. An antibody (IMC-A1) that was 
originally developed for anti-proliferative therapy by inhibition 
of FGFR1 was found to effectively reduce food intake through 
FGFR1c inhibition in the hypothalamus (148). This is in contrast to 
an earlier study that reported increased food intake in response to 
an FGFR1-antibody, targeting FGFR1 in the hypothalamus (105).
Another interesting antibody that can improve metabolic 
dysfunction is the FGF21-mimetic antibody, R1MAb1, devel-
oped by Genentech (149). Although designed to mimic FGF21, 
this antibody activates the b and c splice variants of FGFR1 
independent of β-klotho. It differs from FGF21 in these aspects, 
since FGF21 is β-klotho dependent and also activates FGFR2c 
and FGFR3c. Injection of R1MAb into obese mice had effects 
highly similar to FGF21 treatment, and included improvement 
of serum insulin, lipid, and blood glucose levels and increased 
energy expenditure. R1Mab stimulated ERK signaling in adipose 
tissue, but not in the liver (149).
A different FGF21 mimetic is mimAb1, developed by 
Amgen. This antibody only activates the FGFR1c splice variant, 
and is dependent on β-klotho to establish efficient signaling. 
Administration of mimAb1 to obese monkeys decreased body 
weight and improved several metabolic parameters, including 
plasma glucose and triglyceride levels. In addition, with a half-life 
of 11 days it is highly stable and long-acting. Since the metabolic 
effects of mimAb1 were not observed in WAT-specific FGFR1 
KO mice, it was suggested that these effects are mainly mediated 
though the adipose tissue (150). A similar antibody (C3201-HSA) 
that has specific binding affinity for FGFR1 and human/monkey 
β-klotho was also developed by Amgen. This compound also 
greatly improved the metabolic profile of obese monkeys. Due to its 
high binding affinity for the human form of β-klotho, this antibody 
would be particularly suitable for use in human patients (151).
A slightly different FGFR1/β-klotho-activating antibody 
(bFKB1) also improved the metabolic profile of obese mice. 
Administration bFKB1 led to weight loss, BAT activation, and an 
overall improved metabolic profile but did not lead to elevated 
corticosterone levels. Interestingly, it did induce signaling in the 
adipose tissues and pancreas, but not in the liver and brain (152). 
Conversely, an antibody designed by AstraZeneca, R1c mAb, 
which also specifically targets FGFR1c, is thought to mainly exert 
its effects via the brain where it suppressed food intake (153). This 
indicates that both targeting the peripheral tissues and/or the 
brain can be successful in improving the metabolic status.
CONCLUSiON AND FUTURe 
PeRSPeCTiveS
The identification of several FGFs as hormones with high rele-
vance to metabolic regulation has led to a revival of interest in this 
family. During normal physiology, FGF1, FGF15/19, and FGF21 
have all been shown to regulate distinct but overlapping meta-
bolic processes in a variety of metabolic cell types and tissues. The 
expression of FGFRs, cofactors and cell surface molecules and the 
affinity of different FGFs for these factors allow for this differential 
regulation. In addition, it has been shown that pharmacological 
administration to obese animals greatly improves their metabolic 
profiles and that WAT, liver and brain are important players in 
modulating these effects. Activation of FGFR1 seems central to 
modulating the beneficial metabolic effects.
Even though little is known about the intracellular events 
that underlie the metabolic responses to FGFs, great progress 
has been made in the development of FGF-based drugs. The 
use of chimeras of different FGFs has been instrumental in 
elucidating the functional roles of different domains in the 
FGFs and has resulted in greatly improved pharmaceutical 
properties (16, 34, 139). Targeting of FGFR1 with specific acti-
vating antibodies might be a viable approach to treat metabolic 
disease as well.
Within 10  years of its discovery as a metabolic hormone, 
FGF21 has made it from an obscure FGF to a serious candidate 
in the treatment of metabolic conditions. This holds promise for 
FGF1, of which its pharmacological properties were only recently 
discovered (16). In addition, it may be worthwhile to investigate 
whether individuals with defective FGF signaling are more 
prone to the development of metabolic aberrations, which might 
contribute to the development of more suitable treatments for 
these particular patients. We expect that further understanding 
of the tissues, receptors, and signaling pathways involved in the 
different metabolic improvements induced upon administration 
of FGFs and/or their pharmacologically improved variants will 
greatly aid in the development of safe, effective, and specific drugs 
for the treatment of metabolic disorders.
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